Title: 2025-2026 Regular Session HB 1439 PN 1678 Bill Text (HTM)
Official Title: 
Number of Sections: 1
Source: versions - Printer's No. PN1678
Media Type: text/html

================================================================================

Section 1:
2025-2026 Regular Session HB 1439 PN 1678 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1678 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE BILL No.1439 Session of 2025 INTRODUCED BY O'MARA, C. WILLIAMS, MADDEN, RABB, KHAN, SANCHEZ, STEELE, BURGOS, HOHENSTEIN, HILL-EVANS, CERRATO, RIVERA, GILLEN, BOROWSKI, GIRAL, STENDER, TAKAC AND JAMES, MAY 12, 2025 REFERRED TO COMMITTEE ON HEALTH, MAY 12, 2025 AN ACTAmending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for authority to control.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Section 3 of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, is amended by adding a subsection to read:Section 3. Authority to Control.--* * *(b.1) Notwithstanding subsection (a) or (c)(1), immediately upon approval by the United States Food and Drug Administration, the pharmaceutical composition of crystalline polymorph psilocybin shall be scheduled in a manner to coincide with 123456789101112131415161718192021 Federal law, including 21 U.S.C. Ch. 13 Subch. I (relating to control and enforcement), regulations promulgated under 21 CFR Ch. II (relating to drug enforcement administration, Department of Justice) or any Federal judicial order. Within five business days following rescheduling by the United States Drug Enforcement Administration of the pharmaceutical composition of crystalline polymorph psilocybin, the secretary shall transmit notice of the rescheduling to the Legislative Reference Bureau for publication in the next available issue of the Pennsylvania Bulletin. The rescheduling shall take effect thirty days after the publication in the Pennsylvania Bulletin.* * *Section 2. This act shall take effect immediately.20250HB1439PN1678 - 2 - 12345678910111213


================================================================================

Raw Text:
2025-2026 Regular Session HB 1439 PN 1678 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1678 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE BILL No.1439 Session of 2025 INTRODUCED BY O'MARA, C. WILLIAMS, MADDEN, RABB, KHAN, SANCHEZ, STEELE, BURGOS, HOHENSTEIN, HILL-EVANS, CERRATO, RIVERA, GILLEN, BOROWSKI, GIRAL, STENDER, TAKAC AND JAMES, MAY 12, 2025 REFERRED TO COMMITTEE ON HEALTH, MAY 12, 2025 AN ACTAmending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for authority to control.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Section 3 of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, is amended by adding a subsection to read:Section 3. Authority to Control.--* * *(b.1) Notwithstanding subsection (a) or (c)(1), immediately upon approval by the United States Food and Drug Administration, the pharmaceutical composition of crystalline polymorph psilocybin shall be scheduled in a manner to coincide with 123456789101112131415161718192021 Federal law, including 21 U.S.C. Ch. 13 Subch. I (relating to control and enforcement), regulations promulgated under 21 CFR Ch. II (relating to drug enforcement administration, Department of Justice) or any Federal judicial order. Within five business days following rescheduling by the United States Drug Enforcement Administration of the pharmaceutical composition of crystalline polymorph psilocybin, the secretary shall transmit notice of the rescheduling to the Legislative Reference Bureau for publication in the next available issue of the Pennsylvania Bulletin. The rescheduling shall take effect thirty days after the publication in the Pennsylvania Bulletin.* * *Section 2. This act shall take effect immediately.20250HB1439PN1678 - 2 - 12345678910111213